Caxton Associates LLP Takes $1.24 Million Position in Exelixis, Inc. $EXEL

Caxton Associates LLP purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 1st quarter, Holdings Channel reports. The fund purchased 33,508 shares of the biotechnology company’s stock, valued at approximately $1,237,000.

Several other large investors have also recently bought and sold shares of the business. Fred Alger Management LLC raised its position in Exelixis by 45.9% during the first quarter. Fred Alger Management LLC now owns 21,094 shares of the biotechnology company’s stock valued at $779,000 after buying an additional 6,641 shares during the period. Goldman Sachs Group Inc. increased its stake in Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the period. Kestra Investment Management LLC increased its stake in Exelixis by 1,639.0% in the 1st quarter. Kestra Investment Management LLC now owns 20,155 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 18,996 shares during the period. Scientech Research LLC increased its stake in Exelixis by 2.6% in the 1st quarter. Scientech Research LLC now owns 24,651 shares of the biotechnology company’s stock valued at $910,000 after buying an additional 629 shares during the period. Finally, NFJ Investment Group LLC increased its stake in Exelixis by 244.7% in the 1st quarter. NFJ Investment Group LLC now owns 207,746 shares of the biotechnology company’s stock valued at $7,670,000 after buying an additional 147,471 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $38.28 on Wednesday. The firm has a market cap of $10.31 billion, a price-to-earnings ratio of 18.40, a P/E/G ratio of 0.78 and a beta of 0.32. The business’s 50-day simple moving average is $40.38 and its 200-day simple moving average is $39.61. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

EXEL has been the topic of several research reports. UBS Group set a $38.00 price objective on shares of Exelixis and gave the company a “neutral” rating in a research note on Wednesday, July 30th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Truist Financial dropped their target price on Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Royal Bank Of Canada dropped their target price on Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 29th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $50.00 target price on shares of Exelixis in a research report on Tuesday, July 29th. Thirteen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.